These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 28647800)

  • 1. Safety and effectiveness of tolvaptan for fluid management after pediatric cardiovascular surgery.
    Katayama Y; Ozawa T; Shiono N; Masuhara H; Fujii T; Watanabe Y
    Gen Thorac Cardiovasc Surg; 2017 Nov; 65(11):622-626. PubMed ID: 28647800
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of tolvaptan in the early postoperative stage after heart valve surgery: results of the STAR (Study of Tolvaptan for fluid retention AfteR valve surgery) trial.
    Nishi H; Toda K; Miyagawa S; Yoshikawa Y; Fukushima S; Kawamura M; Yoshioka D; Saito T; Ueno T; Kuratani T; Sawa Y
    Surg Today; 2015 Dec; 45(12):1542-51. PubMed ID: 26411431
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of Tolvaptan on Fluid Management After Cardiovascular Surgery Using Cardiopulmonary Bypass.
    Ito H; Mizumoto T; Tempaku H; Fujinaga K; Sawada Y; Shimpo H
    J Cardiothorac Vasc Anesth; 2016 Dec; 30(6):1471-1478. PubMed ID: 27591907
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of tolvaptan on renal excretion of electrolytes and urea nitrogen in patients undergoing coronary artery bypass surgery.
    Kato TS; Nakamura H; Murata M; Kuroda K; Suzuki H; Yokoyama Y; Shimada A; Matsushita S; Yamamoto T; Amano A
    BMC Cardiovasc Disord; 2016 Sep; 16(1):181. PubMed ID: 27624603
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A Safety and Efficacy Study of Tolvaptan Following Open Heart Surgery in 109 Cases.
    Kono T; Tayama E; Hori H; Ueda T; Yamaki Y; Tanaka H
    Int Heart J; 2016 Jul; 57(4):496-502. PubMed ID: 27396557
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of short-term administration of tolvaptan after open heart surgery.
    Matsuyama K; Koizumi N; Nishibe T; Iwasaki T; Iwahasi T; Toguchi K; Takahashi S; Iwahori A; Maruno K; Ogino H
    Int J Cardiol; 2016 Oct; 220():192-5. PubMed ID: 27379922
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The efficacy of tolvaptan in the perioperative management of chronic kidney disease patients undergoing open-heart surgery.
    Yamada M; Nishi H; Sekiya N; Horikawa K; Takahashi T; Sawa Y
    Surg Today; 2017 Apr; 47(4):498-505. PubMed ID: 27553014
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predictive factors for responders to tolvaptan in fluid management after cardiovascular surgery.
    Kido T; Nishi H; Toda K; Ueno T; Kuratani T; Sakaki M; Takahashi T; Sawa Y
    Gen Thorac Cardiovasc Surg; 2017 Feb; 65(2):110-116. PubMed ID: 27645146
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and Safety Evaluation of Tolvaptan on Management of Fluid Balance after Cardiovascular Surgery Using Cardiopulmonary Bypass.
    Suehiro Y; Hosono M; Shibata T; Sasaki Y; Hirai H; Nakahira A; Kubota Y; Kaku D; Suehiro S
    Osaka City Med J; 2016 Dec; 62(2):111-119. PubMed ID: 30721586
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of tolvaptan for pediatric patients with congestive heart failure. Multicenter survey in the working group of the Japanese Society of PEdiatric Circulation and Hemodynamics (J-SPECH).
    Higashi K; Murakami T; Ishikawa Y; Itoi T; Ohuchi H; Kodama Y; Honda T; Masutani S; Yamazawa H; Senzaki H; Ishikawa S
    Int J Cardiol; 2016 Feb; 205():37-42. PubMed ID: 26710331
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of tolvaptan in patients with chronic kidney disease and chronic heart failure.
    Katsumata M; Hirawa N; Sumida K; Kagimoto M; Ehara Y; Okuyama Y; Fujita M; Fujiwara A; Kobayashi M; Kobayashi Y; Yamamoto Y; Saka S; Yatsu K; Fujikawa T; Toya Y; Yasuda G; Tamura K; Umemura S
    Clin Exp Nephrol; 2017 Oct; 21(5):858-865. PubMed ID: 28190113
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of tolvaptan after pediatric congenital heart disease surgery.
    Kojima T; Kanai A; Yoshiba S; Kobayashi T; Sumitomo N
    Heart Vessels; 2021 May; 36(5):717-723. PubMed ID: 33388911
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vasopressin-2-receptor antagonism augments water excretion without changes in renal hemodynamics or sodium and potassium excretion in human heart failure.
    Costello-Boerrigter LC; Smith WB; Boerrigter G; Ouyang J; Zimmer CA; Orlandi C; Burnett JC
    Am J Physiol Renal Physiol; 2006 Feb; 290(2):F273-8. PubMed ID: 16189291
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Early introduction of tolvaptan after cardiac surgery: a renal sparing strategy in the light of the renal resistive index measured by ultrasound.
    Kato TS; Ono S; Kajimoto K; Kuwaki K; Yamamoto T; Amano A
    J Cardiothorac Surg; 2015 Nov; 10():143. PubMed ID: 26525900
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Can Tolvaptan Protect Renal Function in the Early Postoperative Period of Cardiac Surgery?　- Results of a Single-Center Randomized Controlled Study.
    Kishimoto Y; Nakamura Y; Harada S; Onohara T; Kishimoto S; Kurashiki T; Fujiwara Y; Nishimura M
    Circ J; 2018 Mar; 82(4):999-1007. PubMed ID: 29467353
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Early treatment with tolvaptan improves diuretic response in acute heart failure with renal dysfunction.
    Matsue Y; Ter Maaten JM; Suzuki M; Torii S; Yamaguchi S; Fukamizu S; Ono Y; Fujii H; Kitai T; Nishioka T; Sugi K; Onishi Y; Noda M; Kagiyama N; Satoh Y; Yoshida K; van der Meer P; Damman K; Voors AA; Goldsmith SR
    Clin Res Cardiol; 2017 Oct; 106(10):802-812. PubMed ID: 28540483
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Urine osmolarity predicts the body weight-reduction response to tolvaptan in chronic kidney disease patients: a retrospective, observational study.
    Iwatani H; Kawabata H; Sakaguchi Y; Yamamoto R; Hamano T; Rakugi H; Isaka Y
    Nephron; 2015; 130(1):8-12. PubMed ID: 25926290
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Impact of chronic kidney disease on the diuretic response of tolvaptan in acute decompensated heart failure.
    Ikeda S; Ohshima K; Miyazaki S; Kadota H; Shimizu H; Ogimoto A; Hamada M
    ESC Heart Fail; 2017 Nov; 4(4):614-622. PubMed ID: 29154417
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Administration of tolvaptan with reduction of loop diuretics ameliorates congestion with improving renal dysfunction in patients with congestive heart failure and renal dysfunction.
    Hanatani A; Shibata A; Kitada R; Iwata S; Matsumura Y; Doi A; Sugioka K; Takagi M; Yoshiyama M
    Heart Vessels; 2017 Mar; 32(3):287-294. PubMed ID: 27385022
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical benefit of tolvaptan in patients with acute decompensated heart failure and chronic kidney disease.
    Uemura Y; Shibata R; Takemoto K; Uchikawa T; Koyasu M; Ishikawa S; Mitsuda T; Miura A; Imai R; Iwamiya S; Ozaki Y; Kato T; Miura T; Watarai M; Murohara T
    Heart Vessels; 2016 Oct; 31(10):1643-9. PubMed ID: 26615607
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.